Preclinical therapeutic intervention studies with an anti-CXCL13 monoclonal antibody accordingly showed comparable effectiveness compared to standard treatments in mouse models of RA (collagen-induced arthritis) and MS (experimental autoimmune encephalomyelitis) [82]. Here, CXCL13 is linked to myeloid sarcoma.